Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy
Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy
复制标题
DOI：
10.1016/s0022-3476(98)70034-4
复制
发表时间：
1998-03-01
影响因子：
5.1
通讯作者：
Ezekowitz, RAB
中科院分区：
文献类型：
--
作者：
Barlow, CF;Priebe, CJ;Ezekowitz, RAB
我们报道了在使用干扰素α -2a （IFN）治疗可能危及生命的血管瘤的过程中，婴儿痉挛性双瘫的发展。从26名接受干扰素治疗的婴儿中选出5名患有双瘫的婴儿。三名婴儿持续双瘫，其余两名婴儿在停用干扰素后明显恢复。磁共振成像显示，除了两例患者轻度至中度延迟髓鞘形成外，没有明显的脑或脊柱异常。在随后的x线检查中，所有5例患者的髓鞘形成正常。我们得出结论，干扰素可以对未成熟的中枢神经系统产生不利影响，并产生痉挛性双瘫，这可能是可逆的。我们建议在干扰素治疗期间仔细评估神经发育状况。
We report the development of spastic diplegia in infants during the course of in terferon Alfa-2a (IFN) therapy for potentially life-endangering hemangiomas. Five infants who displayed diplegia were selected from a group of 26 infants treated with IFN. Diplegia persisted in three infants, and in the remaining two signifcant recovery occurred after IFN was discontinued. Magnetic resonance imaging showed no significant brain or spinal abnormalities except minor to moderate delayed myelination in two patients. Myelination was normal on subsequent radiographic examination in all five patients. We conclude that IFN can adversely affect the immature central nervous system and produce spastic diplegia, which is potentially reversible. We recommend careful clinical assessment of neurodevelopmental status during IFN therapy.